DOCSLIB.ORG

Genetics of Distal Hereditary Motor Neuropathies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetics of Distal Hereditary Motor Neuropathies GENETICSOFDISTALHEREDITARY MOTOR NEUROPATHIES By alexander peter drew A thesis submitted for the Degree of Doctor of Philosophy Supervised by Professor Garth A. Nicholson Dr. Ian P. Blair Faculty of Medicine University of Sydney 2012 statement No part of the work described in this thesis has been submitted in fulfilment of the requirements for any other academic degree or qualification. Except where due acknowledgement has been made, all experimental work was performed by the author. Alexander Peter Drew CONTENTS acknowledgements ............................. i summary .................................... ii list of figures ................................ v list of tables ................................ viii acronyms and abbreviations ..................... xi publications ................................. xiv 1 literature review ........................... 1 1.1 Molecular genetics and mechanisms of disease in Distal Hereditary Motor Neuropathies . .1 1.1.1 Small heat shock protein family . .2 1.1.2 Dynactin 1 (DCTN1).....................9 1.1.3 Immunoglobulin mu binding protein 2 gene (IGHMBP2) 11 1.1.4 Senataxin (SETX)....................... 14 1.1.5 Glycyl-tRNA synthase (GARS)............... 16 1.1.6 Berardinelli-Seip congenital lipodystrophy 2 (SEIPIN) gene (BSCL2)......................... 18 1.1.7 ATPase, Cu2+-transporting, alpha polypeptide gene (ATP7A) 20 1.1.8 Pleckstrin homology domain-containing protein, G5 gene (PLEKHG5)........................... 21 1.1.9 Transient receptor potential cation channel, V4 gene (TRPV4) 22 1.1.10 DYNC1H1 ........................... 23 1.1.11 Clinical variability in dHMN . 24 1.1.12 Common disease mechanisms in dHMN . 29 2 general materials and methods ................. 32 2.1 General materials and reagents . 32 2.1.1 Reagents and Enzymes . 32 2.1.2 Equipment . 33 2.1.3 Plasticware . 33 2.2 Study participants . 34 2.3 DNA methods . 34 2.3.1 DNA extraction from blood . 34 2.3.2 DNA oligonucleotides . 35 2.3.3 PCR protocol . 35 2.3.4 Agarose gel electrophoresis . 36 2.3.5 DNA purification from PCR . 36 2.3.6 DNA sequencing . 37 3 genetic mapping ............................. 39 3.1 Introduction . 39 3.1.1 Overview . 39 3.1.2 Homologous recombination and linkage disequilibrium 39 3.1.3 Genetic linkage analysis . 41 3.1.4 Penetrance in dHMN . 44 3.1.5 Characterisation of dHMN1 in a large Australian family 44 3.1.6 Previous genetic studies in dHMN1 at 7q34-q36 . 44 3.1.7 Hypothesis and aims . 48 3.2 Materials and Methods . 50 3.2.1 Microsatellite analysis . 50 3.2.2 Microsatellite markers . 51 3.2.3 Haplotype analysis . 51 3.2.4 Genetic linkage analysis . 52 3.2.5 Association analysis . 53 3.3 Results . 54 3.3.1 Fine mapping of family CMT54 . 54 3.3.2 Linkage analysis using new markers in CMT54 . 57 3.3.3 Identification of additional dHMN families . 60 3.3.4 Linkage power analysis . 62 3.3.5 Genetic linkage analysis in additional dHMN families . 65 3.3.6 Suggestive linkage in family CMT44 . 65 3.3.7 Uninformative families . 66 3.3.8 dHMN families excluded from 7q34-q36 . 74 3.3.9 Haplotype association analysis . 75 3.4 Discussion . 76 3.4.1 Linkage analysis in CMT54 . 76 3.4.2 Linkage analysis in the extended dHMN cohort . 79 3.4.3 Proportion of dHMN caused by a pathogenic gene at 7q34-q36 . 82 4 analysis of candidate genes .................... 84 4.1 Introduction . 84 4.1.1 Chapter overview . 84 4.1.2 Strategy for gene identification . 84 4.1.3 Identifying genes within a disease interval . 85 4.1.4 Selection of candidate genes . 86 4.1.5 Gene screening methods . 88 4.2 Materials and Methods . 90 4.2.1 In-silico candidate gene prioritisation . 90 4.2.2 PCR and sequencing for gene screening . 90 4.2.3 Analysis of effect of variants on exon splicing . 91 4.2.4 RNA studies of splicing variants . 92 4.2.5 RNA folding prediction . 93 4.3 Results . 94 4.3.1 Positional candidate genes . 94 4.3.2 Functional candidate gene selection . 96 4.3.3 Screening candidate genes . 99 4.3.4 Analysis of the interval defined by significantly associ- ated haplotypes . 106 4.4 Discussion . 107 4.4.1 Gene screening summary . 107 4.4.2 Was the mutation missed? . 108 5 copy number and structural variation ............ 109 5.1 Introduction . 109 5.1.1 CNV and structural variation . 109 5.1.2 CNV in dHMN and related peripheral neuropathies . 112 5.1.3 Methods of detecting CNV . 113 5.1.4 Hypothesis and Aim . 115 5.2 Materials and Methods . 115 5.2.1 Custom CGH Microarray . 115 5.2.2 Array processing . 116 5.2.3 Software Nexus 5 . 117 5.2.4 PCR confirmation of deletions . 118 5.3 Results . 118 5.3.1 Cytogenetic analysis . 118 5.3.2 CNV analysis at 7q34-q36 using aCGH . 119 5.4 Discussion . 130 5.4.1 Summary . 130 5.4.2 Comparison of methods for CNV analysis . 130 5.4.3 Limitations of array-based CGH . 133 6 next generation sequencing of cmt54 ............. 134 6.1 Introduction . 134 6.1.1 NGS technology . 134 6.1.2 NGS of large genomes . 138 6.1.3 Applications of NGS to Mendelian disease . 139 6.2 Materials and methods . 141 6.2.1 NimbleGen array-based targeted sequence capture . 141 6.2.2 454 GS FLX sequencing . 142 6.2.3 NimbleGen array-based exome capture and Solexa se- quencing . 143 6.2.4 Confirmation of sequence variants using Sanger sequencing144 6.2.5 Sequence variant analysis using Galaxy Browser . 144 6.2.6 NGS assembly and annotation using Bowtie and SAMtools144 6.2.7 Unequal coverage comparison . 145 6.2.8 In silico prediction of functional impacts of sequence vari- ants . 145 6.3 Results . 146 6.3.1 Chromosome 7q34-q36 target region sequencing . 146 6.3.2 7q34-q36 sequence variant analysis . 147 6.3.3 Off-target and repeat mapping reads . 154 6.3.4 Exome sequencing . 155 6.3.5 Further sequencing analysis using unequal coverage anal- ysis . 158 6.3.6 Exome wide analysis . 163 6.4 Discussion . 164 6.4.1 Limitations of the NGS analysis . 166 7 exome sequencing of cmt44 .................... 169 7.1 Introduction . 169 7.2 Materials and methods . 170 7.2.1 Exome sequencing . 170 7.2.2 NGS variant analysis . 171 7.2.3 HRM analysis . 172 7.3 Results . 172 7.3.1 Exome sequencing in CMT44 . 172 7.3.2 Clinical detail of CMT44 . 173 7.3.3 MFN2 genotyping in CMT44 using high resolution melt analysis . 177 7.3.4 Exome wide sequence variant analysis in CMT44 . 177 7.3.5 Comparison of SNPs between CMT44 and CMT54 . 179 7.4 Discussion . 179 8 general discussion .......................... 185 8.1 Genetic studies in family CMT54 . 185 8.2 Genetic linkage analysis in additional dHMN families . 190 8.3 Genetic studies in family CMT44 . 191 8.4 Conclusion . 192 a custom gnu bash scripts ...................... 194 a.1 Linkage analysis . 194 a.2 NGS coverage visualisation . 197 a.3 NGS variant comparison with fold coverage analysis . 198 b pcr primers ................................ 205 c pedigrees for additional dhmn families ........... 216 d two point lod scores for additional dhmn families ............................... 230 e multi-point lod scores for additional dhmn families ............................... 240 f 7q34-q36 control haplotypes ................... 249 g 7q34-q36 candidate genes and reported gene expression .............................. 251 h next generation sequencing .................... 255 i cnv identified with array cgh .................. 257 bibliography ................................. 261 ACKNOWLEDGEMENTS It is a pleasure to thank the people who made this PhD project possible. My warmest thanks to my supervisors Professor Garth Nicholson and Dr Ian Blair for your support, encouragement and the opportunities presented to me throughout this project. To Garth, your expertise with the clinical aspects of peripheral neuropathies as well as your academic experience have proved invaluable. To Ian, thank you for your guidance in the lab, the opportunities and resources I was given and the assistance with preparation of my thesis. I am extremely grateful to all participating dHMN family members, without whom this research would not be possible. To my colleagues, in particular, Kelly Williams, for assistance with the targeted sequencing of candidate genes and Jenn Solski, for assistance with sequencing variants identified with NGS. To all the staff and students in the Northcott Neuroscience and Molecular Medicine laboratories, thank you for your friendly assistance over these years. The help of Annette Berryman in the Molecular Medicine office and the procedural guidance of Tracey Dent and Annet Doss in the ANZAC research institute office has been most helpful. The support and encouragement of my friends and family has been essential. My parents, Paul and Josephina Drew, have been a constant source of support, both emotionally and financially during my postgraduate years. Finally, my warmest thanks go to my girlfriend Victoria, without her loving support and patience this thesis would never have been possible. You always bring me joy. This work was supported in part by an Australian Postgraduate Award and funding from the National Health and Medical Research Council of Australia (511941). i SUMMARY The distal hereditary motor neuropathies (dHMN) are a clinically and geneti- cally heterogeneous group of disorders that primarily affect motor neurons, without significant sensory involvement. Using genome wide linkage analy- sis in a large Australian family (CMT54), a form of dHMN was previously mapped by this laboratory, to a 12.98 Mb interval on chromosome 7q34-q36. The axonal neuropathy seen.
Load more

Recommended publications
  • Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice
    Loyola University Chicago Loyola eCommons Biology: Faculty Publications and Other Works Faculty Publications 2013 Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice Mihaela Palicev Gunter P. Wagner James P. Noonan Benedikt Hallgrimsson James M. Cheverud Loyola University Chicago, [email protected] Follow this and additional works at: https://ecommons.luc.edu/biology_facpubs Part of the Biology Commons Recommended Citation Palicev, M, GP Wagner, JP Noonan, B Hallgrimsson, and JM Cheverud. "Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice." Genome Biology and Evolution 5(10), 2013. This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has been accepted for inclusion in Biology: Faculty Publications and Other Works by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. © Palicev et al., 2013. GBE Genomic Correlates of Relationship QTL Involved in Fore- versus Hind Limb Divergence in Mice Mihaela Pavlicev1,2,*, Gu¨ nter P. Wagner3, James P. Noonan4, Benedikt Hallgrı´msson5,and James M. Cheverud6 1Konrad Lorenz Institute for Evolution and Cognition Research, Altenberg, Austria 2Department of Pediatrics, Cincinnati Children‘s Hospital Medical Center, Cincinnati, Ohio 3Yale Systems Biology Institute and Department of Ecology and Evolutionary Biology, Yale University 4Department of Genetics, Yale University School of Medicine 5Department of Cell Biology and Anatomy, The McCaig Institute for Bone and Joint Health and the Alberta Children’s Hospital Research Institute for Child and Maternal Health, University of Calgary, Calgary, Canada 6Department of Anatomy and Neurobiology, Washington University *Corresponding author: E-mail: [email protected].
    [Show full text]
  • Severe Infantile Neuropathy with Diaphragmatic Weakness and Its Relationship to SMARD1
    DOI: 10.1093/brain/awg278 Advanced Access publication September 23, 2003 Brain (2003), 126, 2682±2692 Severe infantile neuropathy with diaphragmatic weakness and its relationship to SMARD1 Matthew Pitt,1 Henry Houlden,2 Jean Jacobs,2 Quen Mok,1 Brian Harding,1 Mary Reilly2 and Robert Surtees1 1Great Ormond Street Hospital for Children and Correspondence to: Dr Matthew Pitt, Department of 2The National Hospital for Neurology and Neurosurgery, Clinical Neurophysiology, Great Ormond Street Hospital London, UK for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK E-mail [email protected] Downloaded from Summary A group of 13 patients with early onset diaphragmatic cord in one patient failed to ®nd any evidence of an palsy in association with a progressive neuropathy is SMA. Four out of the ®ve not tested genetically were presented. All eight of those tested were found to have positive for all diagnostic criteria. None of the cases of mutations in the same gene encoding the immunoglobu- early onset neuropathies or spinal muscular atrophies http://brain.oxfordjournals.org/ lin mu-binding protein 2 (IGHMBP2) in patients with with early respiratory failure reviewed in the literature spinal muscular atrophy (SMA) with respiratory dis- shares the exact characteristics, but many do have very tress type 1. Six out of these eight patients had either close similarities. Their classi®cation varies, but the dis- homozygous or compound heterozygous mutations, and covery of mutations in IGHMBP2 in cases that are vari- two had only a single heterozygous mutation. Detailed ously classi®ed as SMA plus or severe infantile analysis of the clinical picture and the neurophysiologi- neuropathy with respiratory distress points to a need cal and histopathological ®ndings indicated that these for the search for this genetic defect to be widened to patients shared similar characteristics, which were fur- include both groups.
    [Show full text]
  • Tepzz¥ 6Z54za T
    (19) TZZ¥ ZZ_T (11) EP 3 260 540 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.12.2017 Bulletin 2017/52 C12N 15/113 (2010.01) A61K 9/127 (2006.01) A61K 31/713 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 17000579.7 (22) Date of filing: 12.11.2011 (84) Designated Contracting States: • Sarma, Kavitha AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Philadelphia, PA 19146 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Borowsky, Mark PL PT RO RS SE SI SK SM TR Needham, MA 02494 (US) • Ohsumi, Toshiro Kendrick (30) Priority: 12.11.2010 US 412862 P Cambridge, MA 02141 (US) 20.12.2010 US 201061425174 P 28.07.2011 US 201161512754 P (74) Representative: Clegg, Richard Ian et al Mewburn Ellis LLP (62) Document number(s) of the earlier application(s) in City Tower accordance with Art. 76 EPC: 40 Basinghall Street 11840099.3 / 2 638 163 London EC2V 5DE (GB) (71) Applicant: The General Hospital Corporation Remarks: Boston, MA 02114 (US) •Thecomplete document including Reference Tables and the Sequence Listing can be downloaded from (72) Inventors: the EPO website • Lee, Jeannie T •This application was filed on 05-04-2017 as a Boston, MA 02114 (US) divisional application to the application mentioned • Zhao, Jing under INID code 62. San Diego, CA 92122 (US) •Claims filed after the date of receipt of the divisional application (Rule 68(4) EPC). (54) POLYCOMB-ASSOCIATED NON-CODING RNAS (57) This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs.
    [Show full text]
  • | Hai Lala at Matalamitaka Huoleht I
    |HAI LALA AT MATALAMITAKAUS009816096B2 HUOLEHT I (12 ) United States Patent (10 ) Patent No. : US 9 ,816 , 096 B2 Heintz et al. (45 ) Date of Patent: Nov . 14 , 2017 ( 54 ) METHODS AND COMPOSITIONS FOR 6 , 143 , 566 A 11/ 2000 Heintz et al. TRANSLATIONAL PROFILING AND 6 , 156 , 574 A 12 / 2000 Heintz et al. 6 , 252 , 130 B1 6 / 2001 Federoff MOLECULAR PHENOTYPING 6 , 270, 969 B1 8 / 2001 Hartley et al. 6 , 403 ,374 B1 6 / 2002 Tsien et al. (71 ) Applicant: THE ROCKEFELLER 6 , 410 , 317 B1 6 /2002 Farmer UNIVERSITY , New York , NY (US ) 6 , 441 , 269 B1 8 / 2002 Serafini et al . 6 , 485 , 912 B1 11/ 2002 Heintz et al. @ 6 , 495 , 318 B2 12 / 2002 Harney ( 72 ) Inventors: Nathaniel Heintz , Pelham Manor, NY 6 ,635 ,422 B2 10 / 2003 Keene et al. (US ) ; Paul Greengard , New York , NY 6 , 821, 759 B1 11/ 2004 Heintz et al . (US ) ; Myriam Heiman , New York , NY 7 , 098, 031 B2B2 8 /2006 Choulika et al . (US ) ; Anne Schaefer , New York , NY 7 ,297 ,482 B2 11 /2007 Anderson et al . (US ) ; Joseph P . Doyle , New York , NY 7 , 393 , 632 B2 7 / 2008 Cheo et al. 2003 /0119104 A1 6 /2003 Perkins et al . (US ) ; Joseph D . Dougherty , St. Louis , 2004 / 0023256 A1 2 / 2004 Puglisi et al . MO (US ) 2005 / 0009028 Al 1 /2005 Heintz et al. 2006 /0183147 AL 8 /2006 Meyer - Franke (73 ) Assignee : THE ROCKEFELLER 2011/ 0314565 Al 12 /2011 Heintz et al . UNIVERSITY , New York , NY (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 EP 1132479 A1 9 / 2001 WO WO -01 / 48480 A1 7 /2001 U .
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Gene Expression Analysis Reveals Novel Gene Signatures Between Young and Old Adults in Human Prefrontal Cortex
    fnagi-10-00259 August 24, 2018 Time: 10:32 # 1 ORIGINAL RESEARCH published: 27 August 2018 doi: 10.3389/fnagi.2018.00259 Gene Expression Analysis Reveals Novel Gene Signatures Between Young and Old Adults in Human Prefrontal Cortex Yang Hu1,2,3, Junping Pan1, Yirong Xin1, Xiangnan Mi1, Jiahui Wang1, Qin Gao1 and Huanmin Luo1,3* 1 Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, China, 2 Department of Pathology and Pathophysiology, School of Medicine, Jinan University, Guangzhou, China, 3 Institute of Brain Sciences, Jinan University, Guangzhou, China Human neurons function over an entire lifetime, yet the molecular mechanisms which perform their functions and protecting against neurodegenerative disease during aging are still elusive. Here, we conducted a systematic study on the human brain aging by using the weighted gene correlation network analysis (WGCNA) method to identify meaningful modules or representative biomarkers for human brain aging. Significantly, 19 distinct gene modules were detected based on the dataset GSE53890; among them, six modules related to the feature of brain aging were highly preserved in diverse independent datasets. Interestingly, network feature analysis confirmed that the blue modules demonstrated a remarkably correlation with human brain aging progress. Edited by: Panteleimon Giannakopoulos, Besides, the top hub genes including PPP3CB, CAMSAP1, ACTR3B, and GNG3 Université de Genève, Switzerland were identified and characterized by high connectivity, module membership, or gene Reviewed by: significance in the blue module. Furthermore, these genes were validated in mice of Suowen Xu, different ages. Mechanically, the potential regulators of blue module were investigated. University of Rochester, United States Maciej J. Lazarczyk, These findings highlight an important role of the blue module and its affiliated genes in Geneva University Hospitals (HUG), the control of normal brain aging, which may lead to potential therapeutic interventions Switzerland for brain aging by targeting the hub genes.
    [Show full text]
  • Cytotoxicity and Genome-Wide Microarray Analysis of Intestinal Smooth Muscle Cells in Response to Hexavalent Chromium Induction
    Zoological Research 34 (E3): E93−E100 DOI:10.11813/j.issn.0254-5853.2013.E3.E93 Cytotoxicity and genome-wide microarray analysis of intestinal smooth muscle cells in response to hexavalent chromium induction Li-Fang JIN, Yuan-Yuan WANG, Zi-Dong ZHANG, Yi-Meng YUAN, Yi-Rui HU, Yang-Feng WEI, * Jian NI College of Life Science of Shaoxing University, Shaoxing Zhejiang 312000, China Abstract: Chronic ingestion of high concentrations of hexavalent chromium [Cr(VI)] in drinking water induces intestinal tumors in mice; however, information on its toxicity on intestinal smooth muscle cells is limited. The present study aimed to assess the in vitro and in vivo toxicological effects of Cr(VI) on intestinal smooth muscle cells. Human intestinal smooth muscle cells (HISM cells) were cultured with different concentrations of Cr(VI) to evaluate effects on cell proliferation ability, oxidative stress levels, and antioxidant system. Furthermore, tissue sections in Cr(VI) exposed rabbits were analyzed to evaluate toxicity on intestinal muscle cells in vivo. Gene chips were utilized to assess differential gene expression profiles at the genome-wide level in 1 μmol/L Cr(VI) treated cells. Intestinal tissue biopsy results showed that Cr(VI) increased the incidences of diffuse epithelial hyperplasia in intestinal jejunum but caused no obvious damage to the structure of the muscularis. Cell proliferation analysis revealed that high concentrations (≥64 μmol/L) but not low concentrations of Cr(VI) (≤16 μmol/L) significantly inhibited the growth of HISM cells. For oxidative stress levels, the expression of reactive oxygen species (ROS) and nitric oxide (NO) was elevated at high concentrations (≥64 μmol/L) but not at low concentrations of Cr(VI) (≤16 μmol/L).
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Plekhg5-Regulated Autophagy of Synaptic Vesicles Reveals a Pathogenic Mechanism in Motoneuron Disease
    Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 12-1-2017 Plekhg5-regulated autophagy of synaptic vesicles reveals a pathogenic mechanism in motoneuron disease. Patrick Lüningschrör University Hospital Würzburg; University of Bielefeld Beyenech Binotti Max Planck Institute for Biophysical Chemistry, Göttingen Benjamin Dombert University Hospital Würzburg Follow this and additional works at: https://jdc.jefferson.edu/medfp Peter Heimann Univ Persityart of of the Bielef Neureldology Commons AngelLet usPerez-Lar knowa how access to this document benefits ouy University of Bielefeld Recommended Citation Lüningschrör, Patrick; Binotti, Beyenech; Dombert, Benjamin; Heimann, Peter; Perez-Lara, Angel; See next page for additional authors Slotta, Carsten; Thau-Habermann, Nadine; von Collenberg, Cora R.; Karl, Franziska; Damme, Markus; Horowitz, Arie; Maystadt, Isabelle; Füchtbauer, Annette; Füchtbauer, Ernst-Martin; Jablonka, Sibylle; Blum, Robert; Üçeyler, Nurcan; Petri, Susanne; Kaltschmidt, Barbara; Jahn, Reinhard; Kaltschmidt, Christian; and Sendtner, Michael, "Plekhg5-regulated autophagy of synaptic vesicles reveals a pathogenic mechanism in motoneuron disease." (2017). Department of Medicine Faculty Papers. Paper 220. https://jdc.jefferson.edu/medfp/220 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Advances in Prognostic Methylation Biomarkers for Prostate Cancer
    cancers Review Advances in Prognostic Methylation Biomarkers for Prostate Cancer 1 1,2 1,2, 1,2, , Dilys Lam , Susan Clark , Clare Stirzaker y and Ruth Pidsley * y 1 Epigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia; [email protected] (D.L.); [email protected] (S.C.); [email protected] (C.S.) 2 St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales 2010, Australia * Correspondence: [email protected]; Tel.: +61-2-92958315 These authors have contributed equally. y Received: 22 September 2020; Accepted: 13 October 2020; Published: 15 October 2020 Simple Summary: Prostate cancer is a major cause of cancer-related death in men worldwide. There is an urgent clinical need for improved prognostic biomarkers to better predict the likely outcome and course of the disease and thus inform the clinical management of these patients. Currently, clinically recognised prognostic markers lack sensitivity and specificity in distinguishing aggressive from indolent disease, particularly in patients with localised, intermediate grade prostate cancer. Thus, there is major interest in identifying new molecular biomarkers to complement existing standard clinicopathological markers. DNA methylation is a frequent alteration in the cancer genome and offers potential as a reliable and robust biomarker. In this review, we provide a comprehensive overview of the current state of DNA methylation biomarker studies in prostate cancer prognosis. We highlight advances in this field that have enabled the discovery of novel prognostic genes and discuss the potential of methylation biomarkers for noninvasive liquid-biopsy testing.
    [Show full text]
  • CRISPR/Cas9 Interrogation of the Mouse Pcdhg Gene Cluster 4 Reveals a Crucial Isoform-Specific Role for Pcdhgc4
    bioRxiv preprint doi: https://doi.org/10.1101/739508; this version posted August 19, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 2 3 CRISPR/Cas9 interrogation of the mouse Pcdhg gene cluster 4 reveals a crucial isoform-specific role for Pcdhgc4 5 6 Andrew M. Garrett1, 3,*, Peter J. Bosch2, David M. Steffen2, Leah C. Fuller2, Charles G. Marcucci2, Alexis A. 7 Koch1, Preeti Bais3, Joshua A. Weiner2,*, and Robert W. Burgess3,* 8 9 1 Wayne State University, Department of Pharmacology, Department of Ophthalmology, Visual, and 10 Anatomical Sciences, Detroit, MI. 11 2 University of Iowa, Department of Biology and Iowa Neuroscience Institute, Iowa City, IA 12 3 The Jackson Laboratory, Bar Harbor, ME 13 * Co-corresponding authors 1 bioRxiv preprint doi: https://doi.org/10.1101/739508; this version posted August 19, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 14 ABSTRACT 15 The mammalian Pcdhg gene cluster encodes a family of 22 cell adhesion molecules, the gamma- 16 Protocadherins (γ-Pcdhs), critical for neuronal survival and neural circuit formation. The extent to which 17 isoform diversity–a γ-Pcdh hallmark–is required for their functions remains unclear. We used a 18 CRISPR/Cas9 approach to reduce isoform diversity, targeting each Pcdhg variable exon with pooled 19 sgRNAs to generate an allelic series of 26 mouse lines with 1 to 21 isoforms disrupted via discrete indels 20 at guide sites and/or larger deletions/rearrangements.
    [Show full text]